This review explores the oncogenic properties of MYCN and MDM2, highlighting the potential of targeting these pathways for cancer therapy. It focuses on preclinical evidence supporting the efficacy and safety of dual-targeted inhibition of MYCN and MDM2, particularly in neuroblastoma. The review also discusses the potential of combining targeted therapies with immunotherapies and conventional treatments for optimal therapeutic outcomes.
Compuscript LtdJan 29 2025 Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality. Targeting oncogenes and their interactive partners is an effective approach to developing novel targeted therapies for cancer and other chronic diseases. The MYC family of proteins, which are transcription factors, play a pivotal role in many cellular processes.
This comprehensive review published in the Genes & Diseases journal by a team from the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, and Drug Discovery Institute, University of Houston focuses on the oncogenic properties of MYCN and its molecular regulation and encapsulates the major therapeutic strategies being developed based on preclinical findings.
As a key survival signaling pathway, the MDM2/p53 axis is widely involved in the development of many tumors. Preclinical and clinical trials provide evidence to support the notion that inhibition of MDM2 could be a potential therapeutic approach for neuroblastoma. Furthermore, the concept of dual-targeted inhibition, which effectively restrains both MYCN and MDM2, along with other critical molecules in neuroblastoma progression, presents an intriguing strategy.
The authors emphasize that with continued research, innovative strategies, and a commitment to addressing the complexities of cancer biology, the future holds the promise of transformative breakthroughs in cancer therapy. In conclusion, the development of effective small molecules that inhibit both MYCN and MDM2 represents a promising new strategy for the treatment of neuroblastoma and other cancers.Journal reference:Wang, W., et al. .
CANCER THERAPY MYCN MDM2 NEUROBLASTOMA ONCOGENES
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Yale Researchers Develop Novel Cancer Treatment Targeting Multiple Immune Suppression PathwaysYale University scientists have made a groundbreaking discovery in cancer treatment by developing a new approach that targets multiple pro-tumor actions simultaneously. This innovative strategy utilizes Cas13, a gene editing molecule, to silence immune suppression genes within the tumor microenvironment, leading to significant tumor growth reduction across various cancer types.
Read more »
Unveiling the metabolic pathways of Fusobacterium nucleatum in OSCCA recent study has made significant strides in uncovering how the oral microbiome, particularly the bacterium Fusobacterium nucleatum, plays a crucial role in the progression of oral squamous cell carcinoma (OSCC).
Read more »
Calcipotriol-Plus-5-FU Therapy Activates Immune Pathways to Prevent Squamous Cell CarcinomaA new study reveals how topical immunotherapy with calcipotriol and 5-fluorouracil (5-FU) activates immune responses to effectively eliminate precancerous skin lesions and prevent the development of squamous cell carcinoma.
Read more »
Scottish Football Set for Transfer Shake-up to Boost Youth PathwaysA proposed shake-up of Scotland's domestic transfer market aims to create smoother pathways for young footballers to reach the first team. The Scottish Football Association is working with clubs on new proposals, including loan agreements and a potential increase in the academy age.
Read more »
Five beautiful January walks around Merseyside no matter the weatherA few hidden pathways lay tucked away boasting gorgeous views and scenery
Read more »
Jack Butland Nears Rangers Return, Targeting Scottish Cup or Man United ClashJack Butland is set to make his comeback for Rangers after recovering from a leg injury. The goalkeeper aims to return in either the Scottish Cup or the Europa League clash against Manchester United.
Read more »